| Prev Close | 100.31 |
| Open | 100.32 |
| Day Low/High | 98.86 / 100.53 |
| 52 Wk Low/High | 80.69 / 102.32 |
| Volume | 69.53K |
| Avg Volume | 425.10K |
| Exchange | NASDAQ |
| Shares Outstanding | 51.78M |
| Market Cap | 5.24B |
| EPS | 2.50 |
| P/E Ratio | 45.01 |
| Div & Yield | N.A. (N.A) |
Masimo (NASDAQ:MASI) announced today the findings of an abstract presented at Euroanaesthesia 2018 in which researchers compared Masimo noninvasive and continuous hemoglobin (SpHb ®) to intermittent and invasive lab hemoglobin (LabHb) in reflecting...
The Women's Tennis Association (WTA) and Masimo (NASDAQ: MASI) announced today that the WTA's Sport Sciences and Medicine (SS&M) team will immediately begin using Masimo MightySat™ as part of their mission to provide comprehensive care for athletes on the...
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers evaluated the utility of Masimo noninvasive and continuous hemoglobin (SpHb ®) in reducing the number of unnecessary blood transfusions, thus reducing...
The Utah State Legislature and Governor Gary Herbert have recently signed into law the Concurrent Resolution on Deaths From Opioid-Induced Postoperative Respiratory Depression (SCR4).
Masimo (NASDAQ: MASI) today announced its financial results for the first quarter ended March 31, 2018.
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the Deutsche Bank 43rd Annual Health Care Conference at the Intercontinental Hotel in Boston on Tuesday, May 8, 2018 at 9:20 a.
Masimo (NASDAQ: MASI) announced today the use of Masimo technologies - O3 ® regional oximetry and SedLine ® brain function monitoring - in two abstracts presented at the 2018 Annual Meeting of the International Anesthesia Research Society (IARS).
Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the 2018 Annual Meeting of the Network for the Advancement of Patient Blood Management, Haemostatis and Thrombosis (NATA), in which researchers investigated the utility of...
Masimo (NASDAQ: MASI) announced today the release of UniView™, an integrated display of real-time data and alarms from multiple Masimo and third-party devices, designed to reduce clinician cognitive overload and...
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Cairo University in Egypt evaluated the accuracy and trending of Masimo noninvasive and continuous hemoglobin...
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel on Tuesday, March 13, 2018 at 4:20 p.
Today at the 2018 HIMSS Annual Conference, Masimo (NASDAQ: MASI) announced the release of Replica™, an application for smart phones and tablets that works in conjunction with Masimo Patient SafetyNet™*, a...
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the 39th Annual Raymond James Institutional Investors Conference at the Marriott Grande Lakes in Orlando on Wednesday, March 7,...
Masimo (NASDAQ: MASI) today announced its financial results for the fourth quarter ended December 30, 2017.
Masimo (NASDAQ: MASI) announced today that NU Hospitals, a leading nephrology care center in India, has standardized on Masimo technologies across the continuum of care.
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Michigan State University evaluated the performance of noninvasive hemodynamic monitoring (NIHM) using Masimo...
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Bülent Ecevit University in Zonguldak, Turkey compared two noninvasive methods of predicting fluid...
Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse CO-Oximeter ®.
Masimo (NASDAQ: MASI) announced today that it will release fourth quarter and full year 2017 financial results for the period ended December 30, 2017, after the market closes on Tuesday, February 27, 2018.
Masimo (NASDAQ: MASI) announced today FDA clearance of Next Generation SedLine ® brain function monitoring.
Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the annual meeting of the Society for Technology in Anesthesia (STA) in Miami, Florida.
Masimo (NASDAQ: MASI) announced today FDA clearance for home use of the Rad-97™ Pulse CO-Oximeter ®.
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the 36th Annual J.
Masimo (NASDAQ: MASI) announced today the CE marking and release of RD rainbow Lite SET™ sensors, which enable the monitoring of Masimo Oxygen Reserve Index™ (ORi™) and RPVi™, an improved...
Masimo (NASDAQ: MASI) announced today that Artemis Hospital, one of the leading multi-specialty hospitals in the Delhi-NCR region of India, is adopting Masimo Patient SafetyNet™*, a supplemental remote...
Masimo (NASDAQ:MASI) announced today FDA clearance and U.
In conjunction with World Pneumonia Day on Sunday, November 12, Masimo (NASDAQ: MASI) announced its continuing efforts to help combat the global burden of pneumonia.
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the Stifel 2017 Healthcare Conference at the Palace Hotel in New York on Tuesday, November 14, 2017 at 9:30 a.
